Comparative Pharmacology
Head-to-head clinical analysis: GENTAFAIR versus TOBRAMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAFAIR versus TOBRAMYCIN SULFATE.
GENTAFAIR vs TOBRAMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
Aminoglycoside antibiotic; binds to 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
Adults: Tobramycin 3-5 mg/kg/day IV divided every 8 hours, or 5-7 mg/kg/day IV once daily. For inhalation: 300 mg nebulized twice daily.
None Documented
None Documented
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 24-100 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Primarily renal (glomerular filtration) with 90-95% excreted unchanged in urine within 24 hours; biliary/fecal <1%.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic